BRCA1 and serous adenocarcinoma: Among the patients with epithelial ovarian cancer (n = 27), most presented with high-grade serous carcinoma (n = 20, 74.1%) and stage III–IV disease (n = 25, 92.6%), and eight (29.6%) had BRCA1/2 mutation.